Non-opioid EXPAREL provides significant long-lasting pain control while reducing opioid use1-3

EXPAREL vs bupivacaine HCI in total knee arthroplasty (TKA)1
78 percent fewer opioids. 13.6 percent less pain in a study
78 percent fewer opioids in a study
13.6 percent fewer opioids in a study
Results from an EXPAREL Phase 4, double-blind, randomized controlled trial that compared the efficacy and safety of EXPAREL 266 mg (20 mL) (n=70) and bupivacaine HCl (n=69) in a TKA. Primary endpoints: area under the curve of visual analog scale pain intensity scores 12–48 hours postsurgery; total opioid consumption 0–48 hours postsurgery. Rescue opioids for pain were available upon patient request. Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, dizziness and muscle spasms.
Data from patients undergoing a soft-tissue surgery
45 percent fewer opioids. 30 percent less pain in a study
45 percent fewer opioids in a study
30 percent less pain in a study
Results from a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial that evaluated the safety and efficacy of 266 mg (20 mL) EXPAREL in 186 patients undergoing 2- or 3-column excisional hemorrhoidectomy. Primary endpoint: cumulative pain score reflected in area under the curve of numeric rating scale through 72 hours. Placebo was preservative-free saline for injection. Opioid rescue medication (up to 10 mg IM morphine) was available to all patients.
*
Results vs placebo through 72 hours. Opioid reduction calculated based on geometric mean ratio.

EXPAREL prolonged the time to first opioid use by 14 hours2

Median time to first opioid use
EXPAREL extended the time until opioid intervention by 14 hours over placebo
EXPAREL extended the time until opioid intervention by 14 hours over placebo

EXPAREL can reduce or eliminate the need for opioids2†

The clinical benefit of the difference in opioid consumption was not demonstrated in the clinical trials.
Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, dizziness and muscle spasms.